{"prompt": "['needle for each vial. The detailed procedure for vial pooling will be described in the IFU', \"document. If the patient's dose is > 2 mL, a second injection will be required.\", 'Medication administration errors during training will be documented in the electronic Case', 'Report Form (eCRF). If necessary, patients or their HCP may choose to continue', 'administration of emicizumab within the clinic. Compliance in the home setting is to be', 'monitored at each site by reviewing reported hemophilia medication use and recording', 'collected used and unused vials.', 'If the patient forgets or cannot administer emicizumab on the scheduled dosing day,', 'emicizumab should be administered as soon as possible before the day of the next scheduled dose,', 'and then the patient should resume the usual weekly dosing schedule. Do not double doses to make up', 'for a missed dose. All four loading doses of 3 mg/kg should be taken, even if this is done over a period', 'or more than four weeks.', 'Any overdose or incorrect administration of emicizumab should be noted on the Study Drug', 'Administration eCRF. Adverse events associated with an overdose or incorrect', 'administration of emicizumab should be recorded on the Adverse Event eCRF. Section 0', 'summarizes available safety data related to overdosing of emicizumab.', 'Patients and/or caregivers will be provided with alert cards, which they will be requested to', 'carry at all times. These will include guidance on recognizing the signs/symptoms of', 'thromboembolic events or allergic/anaphylactic/anaphylactoid reactions and how to obtain', 'emergency care. In addition, alert cards are designed to notify non-study HCPs that', \"emicizumab will interfere with certain coagulation laboratory tests (see the Investigator's\", 'Brochure for more information) and that the investigator should be contacted for assistance', 'in interpreting the test results.', 'Guidelines for dosage modification and treatment interruption or discontinuation are provided', 'in Section 5.1.1.', '4.3.3', 'Investigational Medicinal Product Accountability', 'Emicizumab, the only IMP in the study, will be provided by the Sponsor. Accountability for', 'each vial is required and the study site will acknowledge the receipt of IMP using the', 'interactive voice or web-based response system (IxRS) to confirm shipment condition and', 'content. Any damaged shipments will be replaced.', 'Used and unused emicizumab vials will be returned by the patients to the study site and', 'appropriately accounted for. Used emicizumab vials will then be disposed of at the study site', 'according to institutional standard operating procedures.', 'Instructions regarding how to handle unused vials should be obtained from the Sponsor. If', \"the investigator prefers to destroy the IMP at his or her site, the site's method of IMP\", 'destruction must be agreed to by the Sponsor. The site must obtain written authorization', 'from the Sponsor before any IMP is destroyed, and IMP destruction must be documented on', 'the appropriate form.', 'Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by', 'the study site should be recorded on the Drug Inventory Log.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '113 / Protocol MO39129, Version 3']['4.3.4', 'Continued Access to Emicizumab', 'The Sponsor will offer continued access to emicizumab to study patients who have shown a', 'demonstrable benefit from emicizumab treatment during this study (as measured by', 'sustained clinical response and/or improvement in clinical symptoms).', 'Continued Access to emicizumab will be provided free of charge, through either an Open', 'Label Extension trial, a Post-Trial Access Program, local Patient Support Programs, or other', 'local access mechanisms according to each country regulation, as described per Global', 'procedural document: Continued Access to Roche Investigational Medicinal Product (SOP-', '0112895), in accordance with the Roche Global Policy on Continued Access to', 'Investigational Medicinal Product, and the Declaration of Helsinki in its 2013 issue.', 'A patient will not be eligible to receive study drug after completing the study if any of the', 'following conditions are met:', \"The study drug is commercially marketed in the patient's country and is reasonably\", \"accessible to the patient (e.g., is covered by the patient's insurance or wouldn't otherwise\", 'create a financial hardship for the patient)', 'The Sponsor has discontinued development of the study drug or data suggest that the', 'study drug is not effective for hemophilia A', 'The Sponsor has reasonable safety concerns regarding the study drug as treatment for', 'hemophilia A', \"Provision of study drug is not permitted under the laws and regulations of the patient's\", 'country.', 'The Roche Global Policy on Continued Access to Investigational Medicinal Product is', 'available at the following Web site:', 'http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf', '4.4', 'CONCOMITANT THERAPY', 'Concomitant therapy includes any medication (e.g., prescription drugs, over-the-counter', 'drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a patient', 'from 4 weeks prior to initiation of emicizumab to the Study Completion/Early Termination Visit', '(or to the Safety Follow-up Visit, if applicable). All such medications should be reported to the', 'investigator and recorded on the Concomitant Medications eCRF.', 'Any hemostatic medications (e.g. bypassing agents) and other medications used to treat or prevent', 'bleeds in the 6-month period prior to starting emicizumab treatment will also be collected (see', 'Section 4.5.5).', '4.4.1', 'Permitted Therapy', 'Concomitant use of the following drugs and therapies will be permitted:', 'Drugs to treat existing conditions at time of study entry, as long as allowed based on eligibility', 'criteria (Section 4.1.1 and Section 4.1.2).', 'During the study, any medication to treat or prevent any medical condition as deemed', 'necessary by the treating physician. If prohibited treatment (see Section 4.4.2) is prescribed or', 'Emicizumab - F. Hoffmann-La Roche Ltd', '114 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}